Trial intelligence / Profile preview

Adjunctive systemic therapy for vulval erosive lichen planus

2014-000547-32Phase 4Completed

Sponsor: University of Nottingham
Start: Apr 2014
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Countries: 1

Overview

Phase 4, randomised, open-label trial of hydroxychloroquine, methotrexate, mycophenolate mofetil, prednisolone and clobetasol in lichen planus (LP) (4 arms), sponsored by University of Nottingham. Primary endpoint: Proportion of patients achieving treatment success at 6 months. Started Apr 2014; status: completed.

Drugs

hydroxychloroquinemethotrexatemycophenolate mofetilprednisoloneclobetasol

Conditions

lichen planus (LP)

Beyond the preview

Go deeper on 2014-000547-32.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2014-000547-32.